Contineum Therapeutics, Inc. (CTNM) vs Oculis Holding AG (OCS)
A side-by-side comparison of Contineum Therapeutics, Inc. and Oculis Holding AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTNM
Contineum Therapeutics, Inc.
$12.48HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
OCS
Oculis Holding AG
$8.65HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — CTNM vs OCS
growth of $100 · dividends reinvested · last 2yCTNM -17.4% (-9.1%/yr)OCS -23.2% (-12.4%/yr)CTNM compounded faster over this window
CTNM OCS
CTNM vs OCS: by the numbers
- •OCS is the larger company ($494M vs $470M market cap).
- •Both run net losses; CTNM's is the smaller (0.00% vs -32724.20% net margin).
Metrics side by side
Valuation
| Metric | CTNM | OCS |
|---|---|---|
| P/S ratio | N/A | 1620.77 |
| P/B ratio | 1.96 | 1.82 |
Profitability
| Metric | CTNM | OCS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -32724.20% |
| ROE | -24.02% | -36.79% |
| ROIC | -27.22% | -39.63% |
Growth (annualized)
| Metric | CTNM | OCS |
|---|---|---|
| Total return CAGR (5Y) | N/A | -2.41% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.